pSivida enters eval agreement

April 6, 2006 – Australian bio-nanotech company pSivida Ltd. (Nasdaq: PSDV) announced it entered into an evaluation agreement with an undisclosed large medical device company to evaluate cardiovascular delivery of drugs using pSivida’s drug delivery technologies.

The agreement follows the company’s announcement in January that it had signed evaluation agreements with various companies, including large global pharmaceutical companies, to evaluate pSivida’s platform technology for their developmental compounds.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.